References

References

  1. Australian Government. TGA update on the proposal for the rescheduling of codeine products 20 December 2016. Available at www.tga.gov.au/media-release/update-proposal-rescheduling-codeine-products
  2. Australian Government. TGA Scheduling delegate’s final decision: codeine, December 2016. Available at www.tga.gov.au/scheduling-decision-final/scheduling-delegates-final-decision-codeine-december-2016
  3. Australian Government. TGA Codeine re-scheduling regulatory impact statement, 2016. Available at www.tga.gov.au/publication/regulation-impact-statement-codeine-re-scheduling
  4. Foley M, Harris R, Rich E, Rapca A, Bergin M, Norman I. The availability of over-the-counter codeine medicines across the European Union. Public Health. 2015; 129: 1465-1470.
  5. Tobin C, Dobbin M, McAvoy. Regulatory responses to over-the-counter codeine analgesic misuse in Australia, New Zealand and the United Kingdom. ANZJPH. 2013; 37 (5): 483-488.
  6. Cairns R, Brown J, Buckley N. The impact of codeine re-scheduling on misuse: a retrospective review of calls to Australia’s largest poison centre. Addiction. 2016; 111: 1848-1853
  7. Australian Therapeutic Guidelines. Analgesic guidelines, 2016. Available at https://tgldcdp.tg.org.au/etgAccess (subscription required).
  8. Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists. Recommendations regarding the use of opioid analgesics in patients with chronic non-cancer pain, 2010. Available at http://fpm.anzca.edu.au/resources/professional-documents
  9. Centre for Disease Control. MMWR CDC guideline for prescribing opioids for chronic pain, 2016. Available at https://www.cdc.gov/media/dpk/prescription-drug-overdose/opioid-prescription-guidelines/dpk-opioid-prescription-guidelines.html
  10. Currow D, Phillips J, Clark K. Using opioids in general practice for chronic non-cancer pain: an overview of current evidence. MJA. 2016; 204 (8): 305-309e2.
  11. Nielsen S, Van Hout MC. Over-the-counter codeine – from therapeutic use to dependence, and the grey areas in between, Curr Topics Behav Neurosci. 2016; Jan 15.
  12. Painaustralia. National Pain Strategy: pain management for all Australians, 2010. Available at www.painaustralia.org.au/advocacy/national-pain-strategy.html
  13. Access Economics. The high price of pain: the economic impact of persistent pain in Australia, 2007. Available at www.bupa.com.au/staticfiles/BupaP3/Health%20and%20Wellness/MediaFiles/PDFs/MBF_Foundation_the_price_of_pain.pdf
  14. Van Hout M, Norman I. Misuse of non-prescription codeine containing products: recommendation for detection and reduction of risk in community pharmacies. Int J Drug Pol. 2016; 27: 17-22.
  15. Neilson S, Cameron J, Pahoki S. Opportunities and challenges: over-the-counter codeine supply from the consumer’s perspective. IJPP. 2013; 21: 161-168.
  16. Cooper R. ‘I can’t be an addict. I am.’ Over-the-counter medicine abuse: a qualitative study. BMJ Open. 2013; 3: 1-9.
  17. Cock V, Edmonds C, Cock C. Complications arising due to codeine containing compound analgesic abuse in patients presenting with primary codeine dependence. Poster at the Australasian Professional Society on Alcohol and other Drugs National Conference, Perth, 2015. https://www.eiseverywhere.com/file_uploads/60bed5769de4145bbbb6cfb0653a8ed4_VictoriaCock_071.pdf
  18. Neilson S, Cameron J, Lee N. Characteristics of a nontreatment-seeking sample of over-the-counter codeine users: implications for intervention and prevention. J Opioid Man. 2011; Sep/Oct: 363-370.
  19. Dutch M. Nurofen Plus misuse: an emerging cause of perforated gastric ulcer. MJA. 2008; 188 (1): 56-57.
  20. Frei M, Nielsen S, Dobbin M, Tobin C. Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases. MJA. 2010; 193 (5): 294-296.
  21. Mills D, Johnson J, Cock V et al. Counting the cost of over-the-counter codeine containing analgesic misuse as measured by data related to hospital admissions to a tertiary teaching hospital over a 5-year period, Presentation at the Australasian Professional Society on Alcohol and other Drugs National Conference, Sydney 2016. Available at https://www.eiseverywhere.com/file_uploads/a5e36f68887d8c77c1a487a94559925b_20_DeannaMill.pdf
  22. McAvoy B, Dobbin M, Tobin C. Over-the-counter codeine analgesic misuse and harm: characteristics of cases in Australia and New Zealand. NZMJ. 2011; 124 (1346): 29-33.
  23. Australian Institute of Health and Welfare. National Drug Strategy Household Survey detailed report 2013, 2014. Available at http://aihw.gov.au/publication-detail/?id=60129549469
  24. Gisev N, Nielsen S, Cama E, Larance B, Bruno R, Degenhardt L. An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia. Eur J Clin Pharamcol. 2016; 72: 469-494.
  25. Robinson G, Robinson S, McCarthy P, Cameron C. Misuse of over-the-counter codeine-containing analgesics: dependence and other adverse effects. NZMJ. 2010; 123 (1317): 59-64.
  26. Australian Commission on Safety and Quality in Health Care. Australian Atlas of Healthcare Variation, 2015. Available at https://www.safetyandquality.gov.au/atlas/
  27. Department of Health and Human Services. Pharmaceutical Services Branch data, 2017.
  28. Department of Health and Human Services. Tasmanian hospitalisation data, 2017.
  29. Roxborough A, Hall W, Burns L, Pilgrim J, Saar E, Nielsen S, Degenhardt L. Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. MJA. 2015; 203 (7): 299e1-299e7.
  30. National Drug and Alcohol Research Centre. A review of opioid prescribing in Tasmania: a blueprint for the future, 2012. Available at https://ndarc.med.unsw.edu.au/resource/review-opioid-prescribing-tasmania-blueprint-future

Previous

Index